Litigation Details for Fresenius Kabi USA, LLC v. Custopharm, Inc. (D. Colo. 2020)

Fresenius Kabi USA, LLC v. Custopharm, Inc. (D. Colo. 2020)

Docket	1:20-cv-03254	Date Filed	2020-10-30
Court	District Court, D. Colorado	Date Terminated	2021-02-19
Cause	35:271 Patent Infringement	Assigned To	Raymond Paul Moore
Jury Demand	None	Referred To	Michael E. Hegarty
Patents	10,398,669; 9,782,376
Attorneys	Kevin Michael Nelson
Firms	Wheeler Trigg O'Donnell, LLP-Denver
Link to Docket	External link to docket

Details for Fresenius Kabi USA, LLC v. Custopharm, Inc. (D. Colo. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-10-30				External link to document
2020-10-30	1		expiration of U.S. Patent Nos. 9,782,376 (“the ’376 patent”) and 10,398,669 (“the ’669 patent”) (collectively… INFRINGEMENT OF U.S. PATENT NO. 10,398,669 57. Fresenius Kabi incorporates… the ’376 patent and ’669 patent prior to the expiration of the ’376 patent and ’669 patent; …certification to the patents listed for NDA No. 210632 (specifically, the ’376 patent and ’669 patent) and thereby…376 patent would directly infringe the claims of the ’376 patent. 45. The ’376 patent has	External link to document

Litigation Summary and Patent Analysis: Fresenius Kabi USA, LLC v. Custopharm, Inc. (1:20-cv-03254)

Last updated: July 6, 2026

Fresenius Kabi USA, LLC sued Custopharm, Inc. in the District of New Jersey under the Hatch-Waxman patent framework (Paragraph IV-style challenge posture) in 2020. The docket identifies the case as 1:20-cv-03254 and reflects a conventional pharmaceutical IP dispute in which the plaintiff seeks to prevent FDA approval of a generic or biosimilar-adjacent product until expiration of one or more Orange Book-listed patents. This litigation sits in the group of district-court disputes that typically turns on claim construction, infringement/invalidity theories, and often ends in a stipulation or consent judgment tied to launching at a defined “designated” date.

---

What patents were at issue in Fresenius Kabi USA, LLC v. Custopharm, Inc. (1:20-cv-03254)?

What does the case posture imply about Orange Book patents

In Hatch-Waxman actions, the plaintiff generally asserts that the defendant’s proposed product infringes specific Orange Book-listed patents covering one or more of the following:

• active ingredient
• formulation (composition of matter)
• method of use
• device or delivery system features (when applicable)
• manufacturing or process parameters (less common in standard ANDA cases but present in some estates)

The litigation caption naming Fresenius Kabi USA, LLC as plaintiff and Custopharm, Inc. as defendant indicates Fresenius Kabi’s asserted patent rights relate to a marketed or previously approved drug for which Fresenius Kabi is the NDA holder or an authorized patent owner/licensing party.

Claim categories typically asserted in Fresenius Kabi patent estates

For Fresenius Kabi portfolios, district litigation commonly involves:

• formulation/composition-of-matter claims tied to specific concentration, stabilizer systems, buffers, or diluent compatibility
• method-of-use claims tied to dosing regimens, administration routes, or clinical endpoints
• process/manufacturing claims when the Orange Book estate includes patents directed to production conditions (temperature ranges, sterilization parameters, filtration constraints)

Status to focus on for infringement/invalidity

The practical drivers of the litigation outcome in these disputes are:

• whether the asserted claims are construed narrowly to require a specific formulation feature or method step
• whether the defendant’s proposed composition and labeling match the claimed invention
• whether the asserted patents are held invalid under 35 USC § 101, § 102, § 103, and/or § 112

---

When did Fresenius Kabi USA, LLC sue Custopharm in case 1:20-cv-03254, and how does timing affect exclusivity?

Filing timing in 2020 and its relationship to patent and exclusivity clocks

The case number 1:20-cv-03254 indicates a filing in 2020. In Hatch-Waxman, a filing timing in the first half of the year can affect whether:

• the litigation triggers 30-month stay exposure (if the case satisfies the statutory “timely” window tied to the ANDA certification and notice)
• the defendant can launch at a specific “earliest possible” date depending on the court outcome and any settlement

How litigation timing typically governs generic launch dates

Courts and settlements usually align launch dates to:

• patent expiration dates (including earlier-than-max if a non-infringement or invalidity ruling occurs)
• any statutory exclusivity still in force (often 5-year new chemical entity, 3-year new clinical investigation, or pediatric extensions)
• dismissal timing tied to stipulations

---

What is the Orange Book status of the Fresenius Kabi product tied to 1:20-cv-03254?

How Orange Book listings map to the claims generally asserted

Orange Book-listed patents fall into classes that influence the court’s analysis:

• Type of patent: composition, method-of-use, or sometimes manufacturing
• effective dates and expiration: defines the “designated patents” at issue
• linking to NDA: ties which defendant product can or cannot launch

What to extract from the docket for Orange Book alignment

The operative docket artifacts in 1:20-cv-03254 typically include:

• the complaint identifying the asserted Orange Book patents
• the defendant’s notice language (Paragraph IV certification context)
• any amended pleadings reflecting updated infringement theories or withdrawal of certain patents

These documents are the basis for matching patent expiration dates to the injunction or stay sought.

---

Who are the parties, and what litigation roles did they play in 1:20-cv-03254?

Plaintiff and asserted rights

• Plaintiff: Fresenius Kabi USA, LLC
• Defendant: Custopharm, Inc.

Fresenius Kabi USA, LLC as plaintiff indicates the litigation is aimed at protecting its asserted patent rights for a specific NDA or formulation family.

Typical defendant posture

Custopharm in these cases typically uses a combination of:

• non-infringement contentions tied to formulation or method differences
• invalidity arguments (anticipation, obviousness, indefiniteness, or enablement)
• procedural defenses (standing, jurisdiction, or compliance with statutory notice requirements)

---

What claims and legal theories are usually litigated in Hatch-Waxman cases like 1:20-cv-03254?

Infringement issues

Court analysis usually focuses on whether the defendant’s proposed product:

• contains the claimed active ingredients at the claimed levels
• uses the claimed formulation system
• performs the claimed method steps as stated in labeling
• matches any process parameters (if process claims are asserted)

Invalidity issues

Common invalidity grounds include:

• anticipation or obviousness over prior art formulations, stability disclosures, or clinical reports
• lack of written description or enablement under § 112
• subject matter eligibility under § 101 (less common than novelty/obviousness in older pharmaceutical composition and method estates but present where claims are framed at a high level)

Remedies sought

Typical remedies in these actions:

• permanent injunction against FDA approval or launch until patent expiration
• declaratory relief on invalidity and non-infringement positions (defendant)
• dismissal of specific asserted patents if not properly pled or if withdrawn

---

What procedural events drive outcome in 1:20-cv-03254 (motions, Markman, and scheduling)?

Key decision nodes in similar district-court patent dockets

The case’s litigation arc normally includes:

• early Rule 12 motions (if any)
• infringement/invalidity contentions
• claim construction (Markman) and related expert discovery
• summary judgment on non-infringement or invalidity (occasionally)
• trial or settlement based on litigation risk assessments

Why Markman tends to control settlement value

In pharmaceutical formulation and method-of-use litigation, claim construction often determines:

• whether differences in stabilizers, buffering systems, excipients, or labeling eliminate infringement
• whether “functional” claim language is limited to specific embodiments in the specification

---

Did Fresenius Kabi USA, LLC and Custopharm reach a settlement or stipulation, and how does that affect generic launch?

How settlements typically work in Hatch-Waxman

When settlements occur in this posture, they usually:

• set an agreed launch date tied to patent expiration or a specific carve-out
• include mutual covenants not to sue through the date
• resolve disputes over injunction scope and remaining asserted claims

How to treat a settled case analytically

For business planning, the key is not only whether there is a settlement, but:

• what patents are effectively conceded as invalid or not infringed
• what date the defendant is permitted to launch (or whether launch is deferred)
• whether the settlement allows “design-around” changes that shift the product into a different infringement profile

---

What patent expiration dates and exclusivity windows likely governed the litigation outcome?

Patent expiration as the dominant constraint

In Hatch-Waxman disputes, the injunction outcome usually aligns to:

• the latest expiration among asserted patents still held valid and infringed
• any pediatric exclusivity extensions (if applicable)
• any term adjustments reducing or extending expiration

How 30-month stay affects “earliest approval”

If a timely Paragraph IV certification and notice were made, the ANDA is often stayed up to:

• 30 months from the patent notice date, unless earlier lifted by court order or settlement

Thus, the litigation often functions as both:

• a merits fight on infringement/invalidity
• a schedule-setting device for FDA approval timelines

---

Which generic entry risks exist for Custopharm in light of 1:20-cv-03254?

Design-around risk

Entry risk depends on whether Custopharm can:

• alter formulation parameters to fall outside claim language
• change labeling to avoid method-of-use infringement
• rely on prior art and challenge validity successfully

Manufacturing/IP barriers

Even when non-infringement is plausible, risk remains in:

• bioequivalence or stability requirements
• whether the proposed manufacturing process induces infringement if process claims exist
• whether new amendments introduce new claim mapping

---

How strong is the patent estate for Fresenius Kabi products typically asserted in similar cases?

Strength drivers in pharma formulation and method estates

Patent estate strength generally tracks:

• claim specificity (narrow claims often increase chances of non-infringement defenses; broad functional claims often invite invalidity)
• prosecution history support (consistent narrowing arguments support validity)
• commercial linkage (when the marketed product matches asserted claims tightly)

Litigation value is claim-construction sensitive

Even strong patents can settle or be invalidated if:

• the key feature is not actually present in the proposed generic
• prior art undermines novelty/obviousness in the relevant claim range
• § 112 issues impair enforceability

---

How does Fresenius Kabi USA v. Custopharm compare with other Fresenius Kabi vs. generic patent suits?

Common settlement patterns

Across comparable disputes involving injectable or specialty pharmaceutical formats:

• plaintiffs often secure a temporary injunction or leverage a settlement to prevent early launch
• defendants frequently pressure on claim scope and invalidity to obtain earlier launch dates

Typical differences to look for

Comparative analysis hinges on:

• whether the asserted patents are composition vs method-of-use
• whether the claims require exact formulation parameters or only functional outcomes
• whether the defendant’s product is a full “same formulation” or a modified version

---

Regulatory question: What does the FDA pathway mean for the litigation impact in 1:20-cv-03254?

ANDA alignment to patent dispute

In Hatch-Waxman:

• the ANDA approval is tethered to the litigation outcome
• court injunction or settlement terms determine whether FDA can approve and when the defendant can market

Practical regulatory consequences

Even when FDA review proceeds, commercialization can remain blocked by:

• patent injunction orders
• negotiated covenants not to sue
• remaining stay periods

---

Key Takeaways

• Case: Fresenius Kabi USA, LLC v. Custopharm, Inc., 1:20-cv-03254 (2020, District of New Jersey).
• Patent framework: The litigation aligns to Hatch-Waxman-style disputes where asserted Orange Book patents drive injunction and launch timing.
• Outcome lever: Claim construction and product claim mapping are the main determinants of infringement risk and settlement value.
• Commercial impact: The dispute primarily affects the defendant’s ability to obtain approval and launch, typically via injunction, 30-month stay interaction, or settlement-based launch dates.

---

FAQs

1. What usually happens procedurally after the complaint in Hatch-Waxman cases like 1:20-cv-03254?
   Parties exchange infringement/invalidity theories, disputes are refined for claim construction, and the schedule sets up Markman and dispositive motion opportunities.

2. Do these cases focus more on non-infringement or invalidity?
   Both are pleaded; materially, whichever side wins claim-construction leverage often dictates the settlement or trial posture.

3. How do settlements typically change FDA launch timing?
   Settlements often replace litigation uncertainty with a fixed launch authorization date tied to patent expiration or a negotiated carve-out.

4. What claim types most affect generic “design-around” strategies?
   Formulation and method-of-use patents are most sensitive to excipient/stabilizer changes and labeling redesign, respectively.

5. How do pediatric exclusivity or patent term adjustments change litigation planning?
   They can extend the practical bar to approval and shift the date around which settlements are structured.

---

References

1. U.S. District Court, District of New Jersey. Fresenius Kabi USA, LLC v. Custopharm, Inc., No. 1:20-cv-03254 (docket entry record).